Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income

Reuters

09/26

Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income

Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2570889183"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570889183\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570889183?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570889183","market":"fut","top_or_hot":-1,"title":"Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-26 21:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02898","symbol_name":"盛禾生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL9dKpSd:1","article_id":"2570889183","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570889183","pubTimestamp":1758892780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02898":"盛禾生物-B","BK1161":"生物科技"},"translate_title":"Sunho Biologics报告称，在利息收入增加的推动下，2025年上半年其他收入增长178%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02898":0.9},"content_text":"Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n    \n\n        Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}